UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________

FORM 8-K

___________

CURRENT REPORT

 Pursuant To Section 13 OR 15(d) Of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):   May 26, 2016

FUTUREWORLD CORP. 
(Exact name of registrant as specified in charter)

(727) 474-1816
 (Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

FORWARD LOOKING STATEMENTS

This Form 8-K and other reports filed by Registrant from time to time with the Securities and Exchange Commission (collectively the "Filings") contain or may contain forward looking statements and information that are based upon beliefs of, and information currently available to, Registrant's management as well as estimates and assumptions made by Registrant's management. When used in the filings the words "anticipate", "believe", "estimate", "expect", "future", "intend", "plan" or the negative of these terms and similar expressions as they relate to Registrant or Registrant's management identify forward looking statements. Such statements reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses that may be acquired by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although Registrant believes that the expectations reflected in the forward looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

FutureWorld announces today that on May 20, 2016, the Company has elected Dr. Bobban Subhadra as the Chief Technology and Operation Officer at Bioceutical Sciences, effective June 1, 2016. Dr. Bobban Subhadra core expertise is in drug target discovery and new drug applications for various indications. He works with early-stage biotech companies to develop and commercialize core platform technologies.

Dr. Subhadra has conducted his doctoral studies in Microbiology and Immunology at School of Medicine, University of New Mexico. After graduating he studied the role of neuroserpin, tissue plasminogen activator, and thyroid hormone in synaptic plasticity and Alzheimer’s disease in mouse models. He has published extensively in prestigious journals including Nature, Science, and Neurochemistry International. With his core expertise in immunology and biochemistry and with 10+ years of industry R & D experience, he has developed numerous patented technologies and products for biochemical, biofuel, and pharmaceutical companies. More recently, as the Director of R & D at Quorum Innovations, he developed and commercialized numerous microbiome technologies.

Dr. Bobban Subhadra and his team at Bioceutical Sciences will focus on the creation of a potential pharmaceutic drug with multiple technologies incorporated into the drug delivery system such as creating hydrophobic a nanoparticle surrounded by a hydrophilic Nano-capsule similar to what liposomal technology can do but with improved efficiency for cellular integration using specifically formulated antigens and improved systemic coverage when implemented into a system; the focus of the drug in a biological system will be determined with future research but has established theoretical applications such as neuropathic pain, esophagitis, and immune enhancement to name a few. With Dr. Bobban Subhadra leading the scientific endeavor, pre-clinical and clinical trials will be highly optimized and organized testing the hypotheses of each independent variable in the most unbiased fashion. The scope of the drug is multifaceted with focuses in: the method of delivery into biological systems, the percentage of effectiveness, and the explorative concerns regarding the system integration of the drug. With the completion of the method of delivery technology for this current drug, Bioceutical Sciences’ primary research team can effectively focus on technology for the drug’s application and the drug’s future classification.

FutureWorld is preparing Bioceutical Sciences for the ensuing spin-off.

The FutureWorld Facebook Page (https://www.facebook.com/futureworldcorp)
The Bioceutical Sciences Facebook Page (https://www.facebook.com/ bioceuticalsciences)

The FutureWorld Twitter Feed (https://twitter.com/futureworldinc)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

FutureWorld Corp.

/s/ Sam Talari

Sam Talari

Principal Executive Officer

Dated:  May 26, 2016